RecruitingPhase 2NCT07103746
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Studying Immune-mediated necrotizing myopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Julie Paik, M.D., M.H.S.Johns Hopkins Hospital: Division of Rheumatology
- Intervention
- Ublituximab(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (9)
- University of Alabama at Birmingham School of Medicine: Division of Clinical Immunology & Rheumatology, Birmingham, Alabama, United States
- University of California, Irvine School of Medicine: Division of Rheumatology, Orange, California, United States
- Emory University School of Medicine: Division of Rheumatology, Atlanta, Georgia, United States
- University of Chicago, Department of Medicine: Rheumatology, Chicago, Illinois, United States
- Johns Hopkins Hospital: Division of Rheumatology, Baltimore, Maryland, United States
- Mayo Clinic: Division of Rheumatology, Rochester, Minnesota, United States
- Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology, Great Neck, New York, United States
- University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology, Pittsburgh, Pennsylvania, United States
- University of Texas - Houston, Houston, Texas, United States
Collaborators
Autoimmunity Centers of Excellence · TG Therapeutics · Rho Federal Systems Division, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07103746 on ClinicalTrials.govOther trials for Immune-mediated necrotizing myopathy
Additional recruiting or active studies for the same condition.